The NRF2 antagonist ML385 inhibits PI3K‐mTOR signaling and growth of lung squamous cell carcinoma cells

BACKGROUND: Lung squamous cell carcinoma (LUSC) currently has limited therapeutic options because of the relatively few validated targets and the lack of clinical drugs for some of these targets. Although NRF2/NFE2L2 pathway activation commonly occurs in LUSC, NRF2 has predominantly been studied in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Lili, Moghal, Nadeem, Zou, Xinru, Fang, Yixuan, Hu, Shuning, Wang, Yuhui, Tsao, Ming Sound
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028163/
https://www.ncbi.nlm.nih.gov/pubmed/36305267
http://dx.doi.org/10.1002/cam4.5311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028163/
https://www.ncbi.nlm.nih.gov/pubmed/36305267
http://dx.doi.org/10.1002/cam4.5311

Ejemplares similares